Alterations of the Hippo–YAP pathway are potential targets for oral squamous cell carcinoma (OSCC) therapy, but heterogeneity in this pathway could be responsible for therapeutic resistance. This evidence concerns the gene YAP1 and oral cavity squamous cell carcinoma.